March 06, 2017 - Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has filed a financial statement reporting Revenues of $3,044,000 USD. Previously, on March 06, 2017, Ra Pharmaceuticals, Inc. reported Revenues of $1,884,000 USD. This represents a change of 61.57% in Revenues.
Embed this chart!
<a href="https://fintel.io/fg/us/rarx/Revenues"><img src="https://images.fintel.io/us-rarx-revenues.png" alt="RARX / Ra Pharmaceuticals, Inc. Revenues"><a>
Related News Stories
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M. (30-0)
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-5)
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-17)
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond. (49-2)
This article is the second of two parts discussing Alexion Pharmaceuticals (ALXN) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s competitors back in October, 2017, but there have been some important developments since worth reviewing. Further, given the recent phase 3 success of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), and with results in atypical hemolytic uremic syndrome (aHUS) coming in Q4’18, it now becomes prudent to compare the competitors' drugs to ALXN1210, not just Soliris. (146-2)
Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. Conversely, one mishap can send shares crashing. (220-5)
After getting my toes wet in the renal-disease space with my previous overview article, I came across two companies I really like: Achillion (ACHN) and ChemoCentryx (CCXI). Ra Pharmaceuticals (RARX) and Omeros (OMER) are both contenders with potentially great upside as well, and should be followed closely. (27-2)
Alexion obtains positive phase 3 results for SWITCH study in treating patients with rare blood disease. (58-0)